FDA approves groundbreaking new pancreatic cancer drug

The FDA on Wednesday approved daraxonrasib, a once-daily pill by Revolution Medicines, for advanced pancreatic cancer. Sold as Rasonque, it offers new life-extending care for patients with one of the most aggressive cancers. Approval covers those who already tried other treatments, marking a significant step in oncology.